Coeurative, Inc. is a biopharma company based in Roanoke, VA, dedicated to developing curative strategies for the management of cardiovascular and cardiopulmonary diseases associated with cellular hypoxia. Led by Dr. John F. Schmedtje Jr., a highly experienced cardiologist, the company aims to bring novel coronary vasodilators to clinical practice, leveraging the cellular response to a deficiency in blood and oxygen to open vessels more effectively and selectively than traditional medications.
With a focus on generating nitric oxide in endothelial cells, Coeurative's patented compounds act as vasodilators and modulators of inflammation, addressing the lack of oxygen delivery at the cellular level. The company's innovative pharmaceuticals have potential applications as antianginal agents, secondary prevention for major adverse events in cardiovascular diseases, and even as anti-viral agents targeting COVID-19. With a strong intellectual property portfolio, Coeurative is poised to make significant contributions to the field of cardiovascular medicine.
Generated from the website